MPT Resource Center

MPTs & the IMPT Platform

MPTs & the IMPT Platform May 2021 The MPTs & the IMPT Platform is a PowerPoint presentation created by the IMPT Secretariat at CAMI Health to help our colleagues integrate MPTs into their talks and presentations. Please email IMPT@cami-health.org with any feedback on how you used this information. Download the presentation slide deck CAMI Health […]

TRIO Study Brief: Long-Acting Injections for Women’s HIV Prevention in Sub-Saharan Africa: What End-Users Think

Annual National Reproductive Health Conference

10-13 August 2021 Annual National Reproductive Health Conference San Francisco, CA, USA

Toxicity study considerations for HIV prevention and MPT R&D

Integrating Socio-behavioral & Market Research into MPT R&D: Applying Lessons Learned

TRIO MPT Research Brief: Listening to Young Women in Kenya and South Africa to Inform Multipurpose “2-in-1” Products for HIV and Pregnancy Prevention

TRIO General Research Brief: What End-Users Think About HIV Prevention Products and Multipurpose Prevention Technologies (MPT)

Estimating the market size for a dual prevention pill: adding contraception to pre-exposure prophylaxis (PrEP) to increase uptake

The role of cervicovaginal microbiota on contraceptive and MPT development

Bridging the gap: Advancing multipurpose prevention technologies from the lab into the hands of women

MCI’s Lemonade Stand Series: “Multipurpose Prevention Technologies (MPTs) & Male Contraception

23rd International AIDS Conference (AIDS 2020: Virtual)

Towards a roadmap to advance non-hormonal contraceptive multipurpose prevention technologies: Strategic insights from key stakeholders

A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trial

Toward a Roadmap for Biomedical HIV Prevention Investment Standards: Strategic Insights from Key Industry Stakeholders

Population and the Environment — Time for Another Contraception Revolution

Market Access Framework for MPT Development

This framework is intended to serve as a resource to inform product development and investment decision-making that is focused specifically on market access components of MPT development and introduction—in other words, activities that are critical to ensuring that MPTs in development are not only efficacious in clinical trials, but also desired, acceptable, and accessible to […]

HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial

Topical inserts: A versatile delivery form for HIV prevention

Evaluating Microarray Patches for Long-Acting PrEP and Contraceptives

End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: The Quatro clinical crossover study

Evofem Biosciences reports fourth quarter and year-end 2018 financial results and provides corporate update

MPT Target Population Identification Mapping Tool

A Ten-Year Retrospective Report on the IMPT

An antiviral gel may prevent genital herpes in women

Vaginal ring acceptability and related preferences among women in low- and middle-income countries: A systematic review and narrative synthesis

BU researcher asks, ‘is it time for another contraception revolution?’

Evofem Biosciences enters into financing agreement for up to $80 million, closes first tranche of strategic investment from PDL BioPharma

Better, safer sex: On the hunt for a condom people will actually like

Preferred product attributes of potential multipurpose prevention technologies for unintended pregnancy and sexually transmitted infections or HIV among U.S. women

Assessing the total market for female condoms in Malawi and Zambia

Exploring the Product Development Environment in ARV prevention and MPTs

“We are not the same”: African women’s view of multipurpose prevention products in the TRIO clinical study

How to interest providers and retailers in female condoms

Evofem Biosciences completes phase 2b ‘AMPREVENCE’ trial of Amphora for prevention of chlamydia and gonorrhea in women

Researchers at Queen’s University Belfast have developed a vaginal ring capable of providing sustained delivery of OB-002 (5P12-RANTES) for HIV prevention

MPTs for Reproductive Health

MPTs for Reproductive Health 2019 click to view Factsheet / Outreach Material In this Factsheet / Outreach Material: Health Risk(s): HIV STI / STD Unintended Pregnancy Product Type(s): MPTs Topic(s): Advocacy MPTs Product Development

Fighting HIV/AIDS

Daré Bioscience completes recruitment in pre-pivotal trial of monthly woman-controlled, hormone-free contraceptive candidate, Ovaprene®

The role of antimicrobial peptides in the prevention of sexually transmitted infection (STI)

Tenofovir gel reduces risk for herpes simplex virus type 2 acquisition

Watch: Now a rap song to promote use of condoms

Pre-exposure prophylaxis 2.0: New drugs and technologies in the pipeline

Acceptability of the woman’s condom in a phase III multicenter open-label study

Contraceptive innovation at Women Deliver – A look at the past, the present, the future

Evofem Biosciences announces last patient enrolled for AMPREVENCE, the phase 2b sexually transmitted infections trial of Amphora

Why we need a contraception revolution

The “who” informs the “what”: Identifying the target population in Sub-Saharan Africa to design impactful multipurpose prevention technologies

Integrating preexposure prophylaxis delivery in routine family planning clinics: A feasibility programmatic evaluation in Kenya

HIV prevention research & development investments: Investing to end the epidemic.